A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors

Nuclear Medicine and Biology

Volumn 41, Issue 2, 2014, Pages 133-139

  Durkan, Kubra ^a,b,d   Jiang, Zongrun ^a,c   Rold, Tammy L ^a,b   Sieckman, Gary L ^a   Hoffman, Timothy J ^a,b,c   Bandari, Rajendra Prasad ^a,b   Szczodroski, Ashley F ^a   Liu, Liqin ^e   Miao, Yubin ^e,f,g   Reynolds, Tamila Stott ^a,h   Smith, Charles J ^a,b,c,i  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d EGE UNIVERSITY   (Turkey)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MISSOURI   (United States)

ⁱ The Harry S Truman Veteran's Administration   (United States)

Author keywords

Bombesin; Copper 64; Gastrin releasing peptide; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ARGINYLGLYCYLASPARTYLGLUTAMIC ACID; ARGINYLGLYCYLASPARTYLGLUTAMIC ACID 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID 6 AMINOHEXANOIC ACID PHENYLALANYLGLUTAMINYLTRYPTOPHANYLALANYLGLYCYLHISTIDYL STATINYLLEUCINE AMINE CU 64; CHEMICAL COMPOUND; ECHISTATIN; ECHISTATIN I 125; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; COMPLEX FORMATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TUMOR LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE QUALITY; ISOTOPE TRACING; LIGAND BINDING; MOLECULAR IMAGING; MOUSE; MOUSE MODEL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

BOMBESIN; COPPER-64; GASTRIN-RELEASING PEPTIDE; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN;

AMINOCAPROIC ACID; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; DIMERIZATION; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOACTIVE TRACERS; RECEPTORS, BOMBESIN;

EID: 84892992101     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.11.006     Document Type: Article

References (47)

1. American Cancer Society Cancer facts & figures 2013.
2. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 2008, 34:13-26.
3. Sutherland M., Gordon A., Shnyder S., Patterson L., Sheldrake H. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis. Cancers 2012, 4:1106-1145.
4. Sullivan P.W., Nelson J.B., Mulani P.M., Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2006, 15:1297-1306.
5. Howrey B.T., Kuo Y.F., Lin Y.L., Goodwin J.S. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci 2013, 68:56-61.
6. D'Amico A.V. Prostate-cancer mortality after PSA screening. N Engl J Med 2012, 366:2229-2231. [author reply 30-1].
7. Pool S.E., Krenning E.P., Koning G.A., van Eijck C.H., Teunissen J.J., Kam B., et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010, 40:209-218.
8. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
9. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
10. Smith C.J., Volkert W.A., Hoffman T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 2003, 30:861-868.
11. Varvarigou A., Bouziotis P., Zikos C., Scopinaro F., De Vincentis G. Gastrin-releasing peptide (GRP) analogueues for cancer imaging. Cancer Biother Radiopharm 2004, 19:219-229.
12. 99mTc: a preclinical study. J Med Chem 2005, 48:100-110.
13. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004, 45:1390-1397.
14. 3. Cancer Res 2003, 63:4082-4088.
15. Prasanphanich A.F., Retzloff L., Lane S.R., Nanda P.K., Sieckman G.L., Rold T.L., et al. In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7-14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009, 36:171-181.
16. Yang Y.-S., Zhang X., Xiong Z., Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogues in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33:371-380.
17. Gourni E., Bouziotis P., Benaki D., Loudos G., Xanthopoulos S., Paravatou-Petsotas M., et al. Structural assessment and biological evaluation of two N3S bombesin derivatives. J Med Chem 2009, 52:4234-4246.
18. Scopinaro F., Vincentis G., Varvarigou A., Laurenti C., Iori F., Remediani S., et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003, 30:1378-1382.
19. Schottelius M., Laufer B., Kessler H., Wester H. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
20. Fani M., Maecke H.R., Okarvi S.M. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2012, 2:481-501.
21. Liu S. Radiolabeled multimeric cyclic RGD peptides as Integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3:472-487.
22. Line B.R., Mitra A., Nan A., Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005, 46:1552-1560.
23. Dijkgraaf I., Kruijtzer J.A.W., Frielink C., Corstens F.H.M., Oyen W.J.G., Liskamp R.M.J., et al. αvβ3 Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007, 120:605-610.
24. Blom E., Velikyan I., Estrada S., Hall H., Muhammad T., Ding C., et al. (68)Ga-Labeling of RGD peptides and biodistribution. Int J Clin Exp Med 2012, 5:165-172.
25. Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31:179-189.
26. Beer A.J., Niemeyer M., Carlsen J., Sarbia M., Nährig J., Watzlowik P., et al. Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med 2008, 49:255-259.
27. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET Imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
28. 2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol 2012, 39:377-387.
29. 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009, 50:1168-1177.
30. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009, 36:1483-1494.
31. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009, 20:1016-1025.
32. Chen K., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62:1005-1022.
33. Anderson C.J., Welch M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999, 99:2219-2234.
34. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. PNAS 2007, 104:12462-12467.
35. Abiraj K., Mansi R., Tamma M.-L., Fani M., Forrer F., Nicolas G., et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011, 52:1970-1978.
36. Shi J., Kim Y.S., Zhai S., Liu Z., Chen X., Liu S. Improving tumor uptake and pharmacokinetics of64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 2009, 20:750-759.
37. Maddalena M.E., Fox J., Chen J., Feng W., Cagnolini A., Linder K.E., et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 2009, 50:2017-2024.
38. Liu Z., Yan Y., Chin F.T., Wang F., Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-Labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009, 52:425-432.
39. Li Z.B., Wu Z., Chen K., Ryu E.K., Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 2008, 49:453-461.
40. Yang J., Guo H., Miao Y. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl Med Biol 2010, 37:873-883.
41. 2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010, 37:751-761.
42. Bass L.A., Wang M., Welch M.J., Anderson C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000, 11:527-532.
43. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47:1465-1474.
44. Rogers B.E., Bigott H.M., McCarthy D.W., Della Manna D., Kim J., Sharp T.L., et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogueue. Bioconjug Chem 2003, 14:756-763.
45. 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm 2004, 19:25-34.
46. 3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004, 10:8674-8682.
47. Sun X., Wuest M., Weisman G.R., Wong E.H., Reed D.P., Boswell C.A., et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002, 45:469-477.